Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Secondary Prevention of SBP Recurrence
NCT02011841Phase 3Withdrawn
- Sponsor
- Seoul National University Hospital
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rifaximin in spontaneous bacterial peritonitis (SBP), sponsored by Seoul National University Hospital. Planned start Jan 2014; status: withdrawn.
02
Drugs
rifaximin
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT02011841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02011841.